This week

A research stack and a July FDA hearing both reference thymosin beta-4 — and neither is actually about it

On June 11, Koi Research Labs LLC announced the launch of the Glow Peptide Stack — a research-only formulation bundling GHK-Cu, BPC-157, and TB-500 in lyophilized powder form, with lot-traceable certificates of analysis. The [GlobeNewsWire announcement](https://www.globenewswire.com/news-release/2026/06/11/3310215/0/en/Glow-Peptide-Stack-Launched-by-Koi-Peptides-for-Laboratory-Use.html) describes TB-500 as 'a 43-amino-acid polypeptide related to thymosin beta-4.' Related to. Not the same as. Six weeks from now, on July 23-24, the FDA's Pharmacy Compounding Advisory Committee will convene to evaluate TB-500 for inclusion on the 503A bulk drug substances list — the pathway that would let licensed compounding pharmacies prepare it for patient-specific prescriptions. Thymosin beta-4 itself is not on the PCAC docket. It doesn't need to be, because it's an endogenous peptide your body already synthesizes. The compound heading into the July hearing is the synthetic product that borrowed thymosin beta-4's biology, built a market around it, and then traveled a very different regulatory and evidence path.

The actual biology

An actin-binding peptide your cells already make — one that governs how tissue repairs and reorganizes itself

Thymosin beta-4 is a 43-amino-acid peptide produced throughout the human body, with highest concentrations in tissues actively remodeling, repairing, or under stress. Its primary molecular role is sequestering globular actin — commonly called G-actin — preventing it from polymerizing into filamentous F-actin networks. That sequestration function sounds like a chemistry detail, but its biological consequence is substantial: actin dynamics control how cells migrate, how the cytoskeleton reorganizes during wound repair, and how tissue architecture closes and rebuilds after injury. [The IUPHAR/BPS pharmacology database](https://www.guidetopharmacology.org/GRAC/DatabaseSearchForward?searchString=thymosin+beta-4) documents its signaling roles across tissue types. Beyond actin sequestration, thymosin beta-4 has been studied in cardiac progenitor cell activation, corneal surface restoration, angiogenesis, and inflammation modulation. It is a multifunctional endogenous signaling molecule. That's what thirty years of academic literature is about. And that's what the TB-500 market is borrowing from, with varying degrees of fidelity to the original biology.

The public claim

TB-500 is sold as thymosin beta-4, but they are not the same compound — and the supply chain has known quality problems

The peptide market conflates thymosin beta-4 and TB-500 routinely and often intentionally. TB-500 is sold in different forms across the research market — sometimes as the Ac-LKKTETQ fragment (a seven-amino-acid peptide believed to carry part of the actin-binding activity), sometimes as something much closer in length to the full 43-amino-acid thymosin beta-4. Koi Research Labs' June 11 Glow Stack launch describes TB-500 as 'a 43-amino-acid polypeptide related to thymosin beta-4' — nearly the same length as thymosin beta-4 itself, but the qualifier 'related to' is doing real work in that description. Whether any specific commercial product sold as TB-500 is identical to thymosin beta-4, is a fragment of it, or is something else depends entirely on the batch, the manufacturer, and the quality verification in place. A company survey from Koi found that 75% of lab researchers identified sourcing quality as their primary purchasing concern. That's the research market acknowledging a supply chain integrity issue in real time. The forum recovery narrative around TB-500 — soft-tissue repair, joint relief, faster return from injury — is built on thymosin beta-4 biology and extrapolated to commercial products whose identity is often unverified. Those are two separate claims. Only one has a peer-reviewed foundation.

What the data says

The endogenous peptide has clinical literature — in specific disease contexts, not athletic recovery

Thymosin beta-4 has a real scientific record. The [PubMed literature on thymosin beta-4](https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+beta-4) spans decades of wound healing, regenerative biology, and cardiac research. A 2022 review in PMC — [Progress on the Function and Application of Thymosin β4](https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/) — catalogued its activity across wound closure, angiogenesis, cardiac repair, and inflammation contexts, including analysis of early clinical work. [ClinicalTrials.gov records for thymosin beta-4](https://clinicaltrials.gov/search?term=thymosin+beta-4) include investigational work in cardiac repair, dry eye disease, and ocular surface restoration — areas where the cell-migration and wound-healing biology has the most specific clinical form. The pattern is consistent: when thymosin beta-4 has been studied in humans, the contexts involve damaged or diseased tissues where the repair biology is immediately relevant. The randomized controlled trial evaluating a commercial TB-500 product for athletic recovery in healthy adults does not exist in this literature. The recovery narrative was borrowed from disease-context research and reapplied to a different population, a different product, and a different goal. The July PCAC hearing will not resolve that distinction — it will only answer whether pharmacies can legally compound whatever they call TB-500.

Early human — PeptideFactCheck stance

The tier reflects the biology's promise — not the product market's claims

Thymosin beta-4 holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. The tier is calibrated to the actual record — meaningful preclinical biology, early human clinical investigation in disease-adjacent contexts, and a mechanistic story that academic researchers have found genuinely compelling for decades. What the tier does not do is extend to TB-500 by proximity. The product market borrowed the biology's legitimacy without inheriting the clinical oversight, the identity verification, or the patient-population context that the research was built around. The July 23-24 PCAC hearing is a regulatory question about a compounding pathway — not a scientific verdict on the actin-binding, cell-migration, wound-repair biology of the endogenous peptide. Thymosin beta-4 will keep doing what it does inside human tissue regardless of what the committee decides. The question the evidence can't yet answer — and the PCAC won't answer — is whether a synthetic product claiming to replicate its biology translates to meaningful benefit in a healthy person's recovery context.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.